Texas Clinical Trials Report — June 2026

For Texans considering participation in clinical research, June 2026 presents a critical window of opportunity, especially for studies nearing their enrollment deadlines. A significant 305 clinical trials across the state are slated to close within the next 90 days. This urgent timeframe includes 49 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Act Now: Trials Nearing Their Close

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on various cancers, heart conditions, and liver impairments are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (9 trials)
• Cancer (6 trials)
• Heart failure (6 trials)
• Healthy (6 trials)
• Hepatic impairment (5 trials)
• Breast cancer (5 trials)
• Prostate cancer (5 trials)
• Hypertension (4 trials)
• Solid tumor (4 trials)
• Endometrial cancer (4 trials)

If you or someone you know has one of these conditions, or if you are interested in participating as a healthy volunteer, exploring these options promptly is essential before enrollment windows close.

New Research Frontiers: June's Openings in Texas

This month, Texas welcomes 102 new clinical trials, a slight decrease from the 113 trials that opened in May 2026 but still a robust expansion of research opportunities. The majority of these new studies are drug trials, accounting for 55 of the new openings, followed by other intervention types and device studies.

The new trials address a diverse range of health conditions, with a strong focus on metabolic health and pain management. The most common conditions targeted by these new studies include:

• Obesity (6 trials)
• Type 2 diabetes mellitus (5 trials)
• Overweight (5 trials)
• Chronic weight management (2 trials)
• Healthy adult participants (2 trials)
• Chronic pain (2 trials)
• Pneumococcal disease (2 trials)
• Hypertension (2 trials)
• Back pain (2 trials)
• Diabetes (2 trials)

Leading the charge in new research sponsorship this month are institutions like M.D. Anderson Cancer Center with 11 new trials, and major pharmaceutical companies such as AstraZeneca with 8 new trials and Eli Lilly and Company with 5 new trials. Academic centers, including The University of Texas Health Science Center, Houston, and University of Texas Southwestern Medical Center, are also significant contributors.

Spotlight on Major Phase 3 Trials

June brings several high-profile Phase 3 drug and vaccine trials to Texas, offering access to cutting-edge treatments and preventive measures for widespread health challenges. These studies are often global in scope and involve thousands of participants, representing significant advancements in medical science.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants to evaluate a new treatment for weight management and type 2 diabetes.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc. (a wholly owned subsidiary of Structure Therapeutics). This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron for weight management.
• Pfizer is leading two important Phase 3 vaccine trials for pneumococcal disease. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants to evaluate a combination therapy for T2DM.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• Beyond drug and vaccine development, Convergent Genomics, Inc. is sponsoring NCT07673016, an observational study for "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer," seeking 2,500 participants. The RTI International-sponsored "Collaboration for Down Syndrome Progress (CDP)," NCT07625579, is also recruiting 1,400 participants of all ages to better understand the health and development of people with Down syndrome.

Texas's Expansive Research Landscape

Texas continues to be a powerhouse in clinical research, with a total of 4,837 clinical trials currently recruiting across 173 cities and 4,368 research sites statewide. This month, the majority of new research initiatives are concentrated in the state's major metropolitan areas, ensuring broad access to cutting-edge studies for a large portion of the population. The cities with the most new trials include:

• Houston (46 new trials)
• San Antonio (28 new trials)
• Dallas (24 new trials)
• Austin (16 new trials)
• Fort Worth (5 new trials)
• McKinney (4 new trials)
• El Paso (3 new trials)
• Brownsville (3 new trials)
• Lampasas (3 new trials)
• Irving (3 new trials)

While the major cities are hubs for new research, the presence of trials in over 170 cities demonstrates a commitment to making clinical research accessible across the vast state of Texas.

Participation Opportunities for All Texans

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 102 new trials launched this month, 13 are actively seeking healthy volunteers. Statewide, a total of 500 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Texas are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 12 include children as participants, and 86 include older adults, ensuring that research benefits diverse age groups. Additionally, 8 new trials are female-only, and 2 are male-only, addressing specific health needs. Industry sponsors are driving a substantial portion of new research efforts, with 54 new trials sponsored by pharmaceutical companies, while academic institutions and other organizations contribute significantly to the remaining 48 new studies.

As we move through June, the focus remains on advancing medical knowledge through these diverse and impactful clinical trials across Texas, offering hope and new treatment options for countless individuals.